A humanized monoclonal antibody targeting Staphylococcus aureus
2004; Elsevier BV; Volume: 22; Linguagem: Inglês
10.1016/j.vaccine.2004.08.015
ISSN1873-2518
Autores Tópico(s)Bacterial biofilms and quorum sensing
ResumoThis current presentation describes the in vitro and in vivo characterization of Aurexis® (tefibazumab), a humanized monoclonal antibody that exhibits a high affinity and specificity and for the Staphylococcus aureus MSCRAMM® (Microbial Surface Components Recognizing Adhesive Matrix Molecules) protein ClfA. Aurexis® inhibited ClfA binding to human fibrinogen, and enhanced the opsonophagocytic uptake of ClfA-coated beads. Preclinical in vivo testing revealed that a single administration of Aurexis® significantly protected against an IV challenge with a methicillin resistant S. aureus (MRSA) strain in murine septicemia and rabbit infective endocarditis (IE) models. Safety and pharmacokinetic data from a 19-patient phase I study support continued evaluation of Aurexis® in phase II studies.
Referência(s)